Relmada Therapeutics

Relmada dumps depression asset after slew of phase 3 failures

The biotech has terminated the license agreement for esmethadone, months after canceling two phase 3 trials that were not expected to hit their goals.

Darren Incorvaia Jul 11, 2025 12:12pm

Relmada reconsiders plans to test psilocybin for obesity

Mar 28, 2025 10:00am

Struggling Relmada pays $3M for Tourette's asset from Asarina

Feb 7, 2025 11:00am

Baseball sitting in a glove against a dark background

After 3rd phase 3 strike, Relmada's depression drug is out

Dec 9, 2024 2:30pm

Scorpion taps new CEO, CMO—Chutes & Ladders

Jan 5, 2024 9:30am

Graphic of a business man on a cliffs edge lassoing a declining arrow indicating saving the company andor its value

Relmada's depression med bounces back in open-label trial

Sep 20, 2023 11:00am